Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses recent advancements in congenital adrenal hyperplasia research, including improved diagnostic techniques, alternative treatments, and insights from long-term outcome data, but it reports no new clinical results.

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.

This study found that ethinylestradiol and high-dose cyproterone acetate significantly reduced hirsutism scores and were effective for treating acne and alopecia in women with hyperandrogenism.

This study describes the first case of female pseudohermaphroditism due to a novel homozygous glucocorticoid receptor gene mutation, indicating possible pre- and postnatal virilization in affected females.

Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.

This review discusses the properties and therapeutic potentials of beta-sitosterol, highlighting a need for more detailed studies on its mechanisms and long-term effects in humans; it reports no new results.

This review discusses the chronic nature of acne and its association with various systemic diseases, but reports no new clinical findings, highlighting the need for further study on its nutritional or genetic links.

This review discusses the pathways of androgen biosynthesis and reports no new findings, highlighting the need to understand the interplay between the classic and backdoor pathways.

In this study, Ganoderma lucidum extract was found to significantly inhibit 5alpha-reductase activity and testosterone-induced prostate growth in rats, suggesting potential use for treating benign prostatic hyperplasia.

This study found that 60% of men with mild to moderate androgenetic alopecia showed improvement after treatment with botanically derived 5AR inhibitors, suggesting these compounds may be effective, though larger trials are needed.

In castrated rats, this study found that triterpenoids from Ganoderma lucidum inhibited both types of 5α-reductase and reduced prostate growth linked to testosterone but not dihydrotestosterone.

Both drugs lower DHT levels, with GI198745 being more effective.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This study observed that finasteride use among men with benign prostatic hyperplasia was associated with a decreased incidence of low-grade prostate cancer but not high-grade tumors.

This study reported that certain newly synthesized steroidal derivatives showed stronger inhibitory activity against the 5α-reductase enzyme than finasteride in hamsters, suggesting their potential as enzyme inhibitors.

This article examines the evidence regarding finasteride's sexual side effects and offers recommendations for patient counseling but reports no new clinical findings.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.

This article discusses various causes of hyperandrogenism in women and highlights diagnostic considerations for conditions such as PCOS, NCCAH, Cushing's disease, and androgen-secreting tumors, without reporting new clinical results.

This review details the prevalence and management of ejaculatory disorders in men with benign prostatic hyperplasia-related urinary symptoms and highlights the importance of preserving peri-montanal tissue during treatment to maintain antegrade ejaculation.

This study concluded that finasteride may safely reduce prostate size and improve urinary symptoms for at least six years in men with benign prostatic hyperplasia, though further improvements beyond six months are unlikely.

In this study, men with AGA who took finasteride 5 mg daily for 24 months showed a significant increase in hair counts compared to those who received a placebo.

Acne is significantly influenced by genetics, and understanding its genetic basis could lead to better, targeted treatments.

This review discusses factors affecting fertility in both men and women with congenital adrenal hyperplasia and emphasizes individualized preconception management but reports no new clinical results.

This study developed a theoretical model that suggests finasteride may completely inhibit 5AR type 2, but not sufficiently suppress type 1, leading to only partial reduction of dihydrotestosterone at clinical doses.

This study concluded that men with benign prostatic hyperplasia receiving steroid 5α-reductase inhibitors, such as dutasteride or finasteride, have a higher risk of developing new onset type 2 diabetes compared to those taking tamsulosin.

This case report suggests a possible association between long-term finasteride use for male pattern baldness and the development of cataracts and intraoperative floppy-iris syndrome in a patient.

This study suggests that early onset androgenetic alopecia in men may indicate a male PCOS equivalent, possibly leading to higher risks of metabolic and cardiovascular disorders later in life.

This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.

This review examines the placebo response in conditions such as allergies and weight loss, highlighting its significance in both conventional and alternative medicine randomized trials, without reporting any new results.